Company Overview
Snapshot
Founded in March 2016 by Arik Ben Ishay, Johanan May, and Israel Sarussi, Biobeat operates with 11–50 employees. The company has raised $68.6M across 7 funding rounds from 7 investors. In January 2026, Biobeat secured a Series B funding round led by Ally Bridge Group.
Business overview
Biobeat is a med-tech company specializing in FDA-cleared, cuffless blood pressure monitoring solutions. Its core technology involves a small, non-invasive proprietary PPG sensor placed on a patient's chest for 24 hours, which measures blood pressure, heart rate, and cardiac output. The device and its automated platform deliver detailed reports to clinicians, enabling quick evaluation and treatment adjustments. Biobeat's technology aims to eliminate white coat and masked hypertension by providing continuous, unobtrusive monitoring, serving the health tech and life sciences sectors, particularly in medical devices and digital healthcare for patient remote monitoring.
Strategic signal
In March 2024, Biobeat's new blood pressure patch was featured by News4Jax, highlighting its potential to revolutionize patient monitoring by offering a cuffless solution. This indicates a strong market validation for its innovative technology and suggests a forward trajectory towards broader adoption in remote patient care and hospital-at-home programs, signaling continued growth and impact in the medical device industry.
Log in to access full profile ›Company Intelligence Q&A
- What is Biobeat's primary offering?
- Biobeat provides FDA-cleared, cuffless blood pressure monitoring through a small, non-invasive sensor placed on the patient’s chest for 24 hours, measuring blood pressure, heart rate, and cardiac output.
- Which organization did Biobeat join in September 2022?
- In September 2022, Biobeat joined the Innovators' Network at the American Heart Association Center for Health Technology & Innovation.
- When did Biobeat's remote vital sign monitoring system receive FDA clearance?
- In March 2022, Biobeat's remote vital sign monitoring system received FDA clearance.
- What significant regulatory approval did Biobeat receive in February 2020?
- In February 2020, Biobeat's wearable wristwatch and patch received CE Mark approval for non-invasive cuffless monitoring of blood pressure, cardiac output, stroke volume, pulse, and saturation.